Adar1 Capital Management, LLC Ardelyx, Inc. Transaction History

Adar1 Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$3.28 - $5.51 $1.39 Million - $2.34 Million	424,387 Added 86.48%	915,130 $3.59 Billion
Q1 2025 May 15, 2025	BUY	$4.91 - $6.36 $2.26 Million - $2.92 Million	459,708 Added 1481.26%	490,743 $2.41 Billion
Q4 2024 Feb 13, 2025	BUY	$4.49 - $6.85 $110,611 - $168,749	24,635 Added 384.92%	31,035 $157 Million
Q3 2024 Nov 14, 2024	SELL	$5.28 - $7.57 $335,808 - $481,452	-63,600 Reduced 90.86%	6,400 $44.1 Million
Q2 2024 Aug 13, 2024	BUY	$5.89 - $9.31 $412,300 - $651,700	70,000 New	70,000 $519 Million

245

161M

697K

1.61M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $908M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Adar1 Capital Management, LLC with notifications on news.